Weight loss peptides retatrutide represents one of the most closely watched developments in obesity medicine. Retatrutide is an investigational triple agonist peptide being developed by Eli Lilly, designed to simultaneously target GLP-1, GIP, and glucagon receptors — a mechanism that distinguishes it from currently approved agents such as semaglutide and tirzepatide. Phase 2 trial data published in the New England Journal of Medicine in 2023 generated considerable interest, though retatrutide has not yet received MHRA or EMA marketing authorisation and remains unavailable through NHS or regulated private prescribing pathways.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly subcutaneous peptide that simultaneously activates GLP-1, GIP, and glucagon receptors to reduce appetite, increase energy expenditure, and promote fat breakdown, though it has not yet received MHRA or EMA authorisation.

Retatrutide is an investigational peptide-based medicine being developed by Eli Lilly as a potential treatment for obesity and related metabolic conditions. It belongs to a novel class of agents known as triple agonists, meaning it is designed to target three distinct hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism distinguishes retatrutide from existing approved weight loss peptides such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist), although direct head-to-head trials comparing these agents have not been conducted, and comparative efficacy has not been established.^[2][5]

The pharmacological rationale behind this triple agonism is to engage complementary metabolic pathways simultaneously. GLP-1 receptor activation is thought to reduce appetite, slow gastric emptying, and improve insulin secretion.^[4][5] GIP receptor activation may enhance insulin release and support fat metabolism. Glucagon receptor activation is hypothesised to increase energy expenditure and promote fat breakdown (lipolysis) — though these effects remain under investigation in humans and should not be taken as established clinical outcomes. Together, these actions are theorised to produce a more pronounced and sustained reduction in body weight compared with single or dual receptor agonists; however, this hypothesis requires confirmation from ongoing and future clinical trials.

Retatrutide is administered as a once-weekly subcutaneous injection, consistent with other peptides in this therapeutic class. It is currently under clinical investigation and has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA).^[1][7] As such, it remains an experimental treatment and is not available through standard NHS prescribing pathways.

Clinical Evidence for Retatrutide in Weight Management

Phase 2 trial data (NEJM, 2023) showed approximately 24% mean body weight reduction at the highest dose over 48 weeks; larger Phase 3 TRIUMPH trials are ongoing and required before regulatory submission.

The most significant clinical data for retatrutide to date comes from a Phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023). This trial enrolled adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, and assessed multiple doses of retatrutide against placebo over 48 weeks. Importantly, this trial primarily enrolled people without type 2 diabetes; any potential glycaemic benefits in people with type 2 diabetes remain to be confirmed in dedicated trials. The results were notable: participants receiving the highest dose (12 mg weekly) achieved a mean body weight reduction of approximately 24% from baseline.^[1][7] These findings are not directly comparable to results from trials of semaglutide or tirzepatide, as no head-to-head trials have been conducted; cross-trial comparisons should be interpreted with caution.

Key findings from the Phase 2 trial included:

• Dose-dependent weight loss, with greater reductions observed at higher doses

• Significant improvements in waist circumference, blood pressure, and lipid profiles

• Reductions in fasting glucose and insulin resistance markers, though the clinical significance of these findings in people with type 2 diabetes requires further investigation

• Weight loss appeared to continue throughout the 48-week period without a clear plateau at the highest doses

Whilst these results are encouraging, it is important to contextualise them appropriately. Phase 2 trials are primarily designed to assess safety, tolerability, and dose-finding rather than to confirm efficacy at a population level. Larger Phase 3 trials — the TRIUMPH programme (registered on ClinicalTrials.gov) — are currently underway to evaluate retatrutide across broader populations, including individuals with type 2 diabetes and cardiovascular disease. Until Phase 3 data are published and regulatory review is completed, conclusions about long-term efficacy and safety must remain cautious. NICE guidance on obesity pharmacotherapy is based on robust, peer-reviewed evidence from completed trial programmes, and retatrutide has not yet reached that threshold.

Potential Side Effects and Safety Considerations

The most common side effects are gastrointestinal; glucagon receptor activation may elevate heart rate, and class-level risks include pancreatitis, gallbladder disease, and thyroid C-cell tumours based on animal data.

Based on Phase 2 trial data (Jastreboff et al., NEJM 2023), retatrutide's side effect profile appears broadly consistent with other GLP-1-based therapies, though the addition of glucagon receptor agonism introduces some distinct considerations. The most commonly reported adverse effects were gastrointestinal in nature, including:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects were generally mild to moderate in severity, most prevalent during dose escalation, and tended to diminish over time. Discontinuation rates due to adverse effects were higher in the higher-dose groups, which is an important consideration for tolerability in clinical practice.

The glucagon receptor component of retatrutide raises specific safety questions that require further investigation. Glucagon stimulation can increase heart rate, and elevated pulse rate was observed in trial participants — a finding that warrants careful monitoring, particularly in individuals with pre-existing cardiovascular conditions.^[1][7] Additionally, because glucagon promotes glycogenolysis and gluconeogenesis, there is a theoretical concern regarding glucose management in people with type 2 diabetes, although the GLP-1 and GIP components appear to counterbalance this effect in practice.

As with all GLP-1 receptor agonists, there are class-level safety considerations to be aware of, based on UK Summary of Product Characteristics (SmPC) for approved agents such as semaglutide (Wegovy):

• Pancreatitis: If pancreatitis is suspected — indicated by severe, persistent abdominal pain, which may radiate to the back — treatment should be stopped immediately and urgent medical assessment sought.

• Gallbladder disease: An increased risk of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) has been observed with GLP-1 receptor agonists. Patients experiencing upper abdominal pain or jaundice should seek prompt medical review.

• Dehydration and acute kidney injury: Persistent vomiting or diarrhoea can lead to dehydration, which may impair kidney function. Patients should maintain adequate fluid intake and seek medical advice if symptoms are severe or prolonged.

• Thyroid C-cell tumours: Animal studies (rodents) have identified a signal for thyroid C-cell tumours with GLP-1 receptor agonists; the relevance of this finding to humans is currently unknown.^[11] Patients should be advised to report any symptoms suggestive of thyroid disease, such as a palpable neck lump, difficulty swallowing, or persistent hoarseness, to their clinician promptly. In line with UK SmPCs for approved GLP-1 receptor agonists, clinical vigilance is recommended in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2); use in such individuals is generally not recommended.^[11]

• Concurrent use with other GLP-1 receptor agonists is not recommended.

• Hypoglycaemia: People with type 2 diabetes taking insulin or sulphonylureas alongside GLP-1-based therapies require careful monitoring due to an increased risk of hypoglycaemia.

Patients and healthcare professionals are encouraged to report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Current Availability and Regulatory Status in the UK

Retatrutide has not received MHRA or EMA marketing authorisation and is not available through NHS or regulated private prescribing; patients should not seek it from unregulated online sources.

As of the time of writing, retatrutide has not received marketing authorisation in the United Kingdom.^[1][7] It has not been approved by the MHRA, nor has it received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP). Outside of approved clinical trials — and any future access that might be granted through the MHRA's Early Access to Medicines Scheme (EAMS) — retatrutide is not available for prescription or dispensing in the UK. Patients should not expect to access this medicine through NHS or regulated private pharmacy channels at this time.

The drug is currently progressing through Phase 3 clinical trials under the TRIUMPH programme, which is evaluating its efficacy and safety across a range of populations. Regulatory submission to bodies such as the MHRA or EMA would typically follow the completion and analysis of Phase 3 data. If approved, NICE would then conduct a health technology appraisal to determine whether retatrutide represents a cost-effective use of NHS resources; the duration of this process varies and cannot be predicted with certainty at this stage.

Patients should be aware that some online or private clinics may offer unlicensed or unregulated peptide compounds marketed under similar names. The MHRA has issued repeated warnings about the risks of purchasing unlicensed medicines online, including concerns about product quality, contamination, incorrect dosing, and the absence of medical supervision (see MHRA/GOV.^[12]UK guidance on buying medicines online). Patients are strongly advised not to seek retatrutide or similar compounds from unregulated sources. Anyone interested in weight management pharmacotherapy should consult their GP or a registered specialist, who can discuss currently approved and evidence-based options available through legitimate NHS or regulated private pathways.

Who May Be Suitable for Peptide-Based Weight Loss Treatment?

Currently approved peptide treatments such as semaglutide 2.4 mg (Wegovy) are available under NICE TA875 for adults with BMI ≥35 kg/m² and a weight-related comorbidity, delivered within a specialist weight management service.

Whilst retatrutide itself is not yet available, understanding who might be considered for peptide-based weight loss treatment in the future — and who is currently eligible for approved agents — is clinically relevant. NICE technology appraisal guidance TA875 supports the use of semaglutide 2.4 mg (Wegovy) for adults who meet specific criteria:

• BMI ≥35 kg/m² with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea)

• BMI 30–34.9 kg/m² in certain higher-risk groups

• For people from certain ethnic backgrounds — including South Asian, Chinese, other Asian, Middle Eastern, Black African, and African-Caribbean groups — lower BMI thresholds apply (typically approximately 2.5 kg/m² lower than standard thresholds), in line with NHS and NICE guidance on ethnicity-related metabolic risk

• Treatment must be delivered as part of a specialist weight management service providing multidisciplinary support

• Treatment duration under TA875 is limited to a maximum of 2 years

Should retatrutide receive regulatory approval and a positive NICE appraisal, it is likely that similar eligibility criteria would apply, potentially with additional considerations given its more potent mechanism of action. In line with UK SmPCs for approved GLP-1 receptor agonists, use is generally not recommended in individuals with a personal or family history of medullary thyroid carcinoma or MEN2, or in those with a history of pancreatitis; these would be important factors in any clinical assessment.^[11]

Peptide-based treatments are not a standalone solution and are most effective when used alongside dietary modification, increased physical activity, and behavioural support. They are not appropriate for individuals who are pregnant or breastfeeding. In line with the semaglutide (Wegovy) SmPC, treatment should be discontinued during pregnancy, and women planning a pregnancy are advised to stop treatment at least 2 months beforehand; patients should discuss family planning with their clinician.^[11] People with type 2 diabetes on insulin or sulphonylureas require careful monitoring due to the risk of hypoglycaemia when combining these agents.

Anyone considering weight management treatment — whether pharmacological or otherwise — should begin with a conversation with their GP. A structured assessment of BMI, comorbidities, medication history, and lifestyle factors will help determine the most appropriate and safe pathway, in line with current NICE (TA875) and NHS guidance.

Frequently Asked Questions